Pharmacokinetics and Bioequivalence of Doxylamine + Pyridoxine, Film-coated, Enteric-soluble Tablets, and Diclectin, Delayed Release Tablets, in Healthy Volunteers
- First Posted Date
- 2022-08-12
- Last Posted Date
- 2023-07-27
- Lead Sponsor
- Valenta Pharm JSC
- Target Recruit Count
- 28
- Registration Number
- NCT05498233
- Locations
- 🇷🇺
Llc "Certa Clinic", Moscow, Russian Federation
Efficacy and Safety of Buspirone, Sustained-release Tablets, 15 mg in Patients With Autonomic Dysfunction Syndrome Accompanied by Vertigo
- First Posted Date
- 2022-06-24
- Last Posted Date
- 2022-06-24
- Lead Sponsor
- Valenta Pharm JSC
- Target Recruit Count
- 268
- Registration Number
- NCT05430217
- Locations
- 🇷🇺
Limited Liability Company "MK-Med", Saint Petersburg, Russian Federation
🇷🇺Limited Liability Company "MART", Saint Petersburg, Russian Federation
🇷🇺Saint Petersburg State Budgetary Institution of Healthcare "City Hospital No. 40 of Kurortny District", Saint Petersburg, Russian Federation
Pharmacokinetics and Bioequivalence of Molnupiravir, 200 mg Capsules and Lagevrio, 200 mg Capsules in Healthy Volunteers
- Conditions
- Viral InfectionCOVID-19
- Interventions
- Drug: Molnupiravir
- First Posted Date
- 2022-06-09
- Last Posted Date
- 2023-07-27
- Lead Sponsor
- Valenta Pharm JSC
- Target Recruit Count
- 37
- Registration Number
- NCT05412173
- Locations
- 🇷🇺
Limited Liability Company "Research Center Eco-Safety", Saint Petersburg, Russian Federation
Study of the Effect of Food Intake on the Bioavailability of XC8 10 mg Film-coated Tablets
- First Posted Date
- 2022-03-24
- Last Posted Date
- 2023-07-27
- Lead Sponsor
- Valenta Pharm JSC
- Target Recruit Count
- 24
- Registration Number
- NCT05294250
- Locations
- 🇷🇺
Limited Liability Company "Research Center Eco-Security", Saint Petersburg, Russian Federation
Study of the Effect of Food Intake on the Bioavailability of XC221 100 mg Tablets
- Conditions
- Healthy
- Interventions
- Drug: XC221 100 mg tablets
- First Posted Date
- 2022-03-24
- Last Posted Date
- 2023-07-27
- Lead Sponsor
- Valenta Pharm JSC
- Target Recruit Count
- 24
- Registration Number
- NCT05295121
- Locations
- 🇷🇺
Limited Liability Company "Research Center Eco-Safety", Saint Petersburg, Russian Federation
Efficacy and Safety of XC8, Film-coated Tablets, 40 mg in Patients With Dry Non-productive Cough Against Acute Respiratory Viral Infection
- Conditions
- Common ColdAcute Respiratory InfectionInfluenza, Human
- Interventions
- Drug: XC8, film-coated tablets, 10 mgDrug: Placebo
- First Posted Date
- 2022-03-10
- Last Posted Date
- 2023-07-27
- Lead Sponsor
- Valenta Pharm JSC
- Target Recruit Count
- 250
- Registration Number
- NCT05273619
- Locations
- 🇷🇺
EosMED JSC, Saint Petersburg, Russian Federation
🇷🇺OrKli Hospital LLC., Saint Petersburg, Russian Federation
🇷🇺Ivanovo Kuvaev Clinical Hospital, Ivanovo, Russian Federation
Efficacy and Safety of XC8, Film-coated Tablets, 10 mg in Patients With Dry Non-productive Cough Against Acute Respiratory Viral Infection
- Conditions
- Common ColdInfluenza, HumanAcute Respiratory Infection
- Interventions
- Drug: XC8, film-coated tablets, 80 mg/dayDrug: PlaceboDrug: XC8, film-coated tablets, 20 mg/dayDrug: XC8, film-coated tablets, 40 mg/day
- First Posted Date
- 2022-03-08
- Last Posted Date
- 2022-03-08
- Lead Sponsor
- Valenta Pharm JSC
- Target Recruit Count
- 160
- Registration Number
- NCT05269329
- Locations
- 🇷🇺
Kirov State Medical University, Kirov, Russian Federation
🇷🇺Professors' Clinic LLC., Perm, Russian Federation
🇷🇺Medical Diagnostic Center LLC., Yaroslavl, Russian Federation
Efficacy and Safety of Ingavirin®, Syrup, 30 mg/5 ml, in Children With Influenza and Other Acute Respiratory Viral Infections
- Conditions
- Influenza, HumanAcute Respiratory InfectionCommon Cold
- Interventions
- Drug: Ingavirin®, syrup, 30 mg/5 mlDrug: Placebo
- First Posted Date
- 2022-03-07
- Last Posted Date
- 2023-07-27
- Lead Sponsor
- Valenta Pharm JSC
- Target Recruit Count
- 240
- Registration Number
- NCT05269290
- Locations
- 🇷🇺
Bashkir State Medical University, Ufa, Russian Federation
🇷🇺Federal Research and Clinical Center of Physical and Chemical Medicine of the Federal Medical and Biological Agency, Odintsovo, Moscow Region, Russian Federation
🇷🇺PiterKlinika LLC, Saint Petersburg, Russian Federation
Efficacy and Safety of Ingavirin®, 90 mg Capsules in Patients With COVID-19
- Conditions
- COVID-19
- Interventions
- Drug: Ingavirin®, 90 mg capsulesDrug: Placebo
- First Posted Date
- 2022-01-31
- Last Posted Date
- 2023-07-27
- Lead Sponsor
- Valenta Pharm JSC
- Target Recruit Count
- 233
- Registration Number
- NCT05216497
- Locations
- 🇷🇺
"Family Clinic" LLC, Ekaterinburg, Russian Federation
🇷🇺St. Petersburg State Budgetary Healthcare Institution "City Polyclinic No. 117", Saint Petersburg, Russian Federation
🇷🇺Unimed-C Jsc, Moscow, Russian Federation
A Study to Evaluate the Safety, Tolerability and Efficacy of XC221 in Patients With Uncomplicated Influenza or Other Acute Viral Upper Respiratory Infections
- Conditions
- InfluenzaViral Respiratory InfectionAcute Viral Upper Respiratory Infections
- Interventions
- Drug: XC221 200 mgDrug: XC221 100 mgDrug: Placebo
- First Posted Date
- 2021-09-01
- Last Posted Date
- 2023-07-27
- Lead Sponsor
- Valenta Pharm JSC
- Target Recruit Count
- 255
- Registration Number
- NCT05030324
- Locations
- 🇷🇺
Limited Liability Company "Health Energy", Saint Petersburg, Russian Federation
🇷🇺Limited Liability Company "MEDICAL CLINIC", Saint Petersburg, Russian Federation
🇷🇺State autonomous health care institution "Engels City Clinical Hospital No. 1", Engels, Russian Federation